The FDA has approved Theravance Inc. and Astella Pharma Inc."s Vibativ [telavancin], a once-daily infusion antibiotic to treat difficult skin infections such as methicillin-resistant Staphylococcus aureus, or MRSA. It will come with a "black- box" warning for pregnant women.